Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial
Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial
Teva
NYSE: TEVA $36.36 USD
Antibodies
Company Info
Recent News
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
Teva saddles up as bidder for bankrupt BioXcel's CNS assets
Teva saddles up as bidder for bankrupt BioXcel's CNS assets
Teva's patent and communications strategies in Turkey face probe
Teva's patent and communications strategies in Turkey face probe
Appeals court sides partially with Teva in IRA pricing lawsuit
Appeals court sides partially with Teva in IRA pricing lawsuit